Introduction

Bronchiolitis obliterans (BO) is a chronic irreversible, non-progressive and obstructive lung disease that is characterized by inflammatory reaction, and that develops following severe injury to the lower respiratory tract [1]. The condition should be considered when making a diagnosis in the presence of persistent wheezing and cough and auscultation findings 6–8 weeks after an episode of pneumonia [1,2]. We present here a case diagnosed with post-infectious bronchiolitis obliterans after a cough and wheezing episode of pneumonia [1,2].

Case

A 5.5 month-old male patient presented with complaints of wheezing and cough for 1.5 months to the outpatient pediatric pulmonary diseases clinic, due to an increase in the severity of the complaints over the last 2 weeks. It was learned from prenatal history that the patient had been born to a 19-year-old G1P1A0 mother at 38 weeks and 2 days by Cesarean section, with a birth weight of 3435g. In the absence of spontaneous respiration, positive pressure ventilation (PPV) was applied and the patient was admitted to the intensive care unit for 5 days for respiratory injury to the lower respiratory tract [1]. The condition should be considered when making a diagnosis in the presence of persistent wheezing and cough and auscultation findings 6–8 weeks after an episode of pneumonia [1,2].

The patient's viral respiratory tract panel was normal, and no other agent was detected, and so the patient was considered to have post-infectious bronchiolitis obliterans (PIBO), developing after a COVID-19 infection. Oxygen support was started through a mask with a reservoir bag, since the oxygen saturation of the patient was borderline low. He was treated with azithromycin for 5 days and methylprednisolone at a dose of 1 mg/kg/day. No need for oxygen was identified starting from the third day of the treatment, and the patient’s retractions resolved. Blood was drawn for peripheral lymphocyte subgroup measurements prior to the start of methylprednisolone treatment, and the results were within the normal range. The patient underwent oral methylprednisolone treatment for 14 days and azithromycin prophylaxis on three days a week was prescribed as a discharge treatment. Inhaler fluticasone propionate was planned after the 14-day methylprednisolone treatment was concluded (Figures 1 and 2).
Bronchiolitis obliterans refers to the partial or total obstruction of the respiratory and terminal bronchioles through inflammation and fibrosis. It may develop after bone marrow or lung transplants, and less frequently after the respiration of toxic materials, being a condition associated with aspiration and connective tissue diseases [1,2]. The most common type, known as post-infectious bronchiolitis obliterans (PBO), is seen secondary to respiratory tract viral pathogens. The most frequently detected viral pathogens are adenoviruses [4]. In the case presented here, the causative pathogen was considered to be COVID-19, given the family history of COVID-19 in the patient’s father 6-8 weeks earlier, the fact that no other viral pathogen grew on the viral respiratory tract panel, and the positive COVID-19 antibody test. To the best of our knowledge, this is the first case of COVID-19-associated PBO to be presented in literature.

The onset of the disease mimics viral bronchiolitis clinically. The presence of tachypnea and fever, the development of a supplemental oxygen requirement, and the auscultation of diffuse rales on physical examination for 6–8 weeks should bring PBO to mind [5]. In the present case, the complaints of wheezing and cough that had started at the beginning of the infection had continued for 6 weeks. Disease diagnosis is supported by thoracic CT findings, with areas of air trapping, mosaic attenuation, peribronchial thickening and a ground glass appearance, and central bronchiectasis at advanced stages being detected [6]. In the present case, the ground glass appearance and the mosaic pattern associated with areas of air trapping was seen.

Anti-inflammatory agents are suggested for treatment, since the obliteration in the lungs is considered to be due to inflammation, although no there are a lack of studies investigating PBO treatments [7]. The first choice agents are corticosteroids, since they prevent fibrosis, while pulse corticosteroid treatment has been used in some studies as an alternative to long-term oral corticosteroids, and is considered to cause less exposure to the long-term side effects of oral steroids [1]. The present case was started on oral corticosteroids, given his a very young age and the low severity of the disease, and the treatment was planned to be changed subsequently to inhaler corticosteroids.

The presence of an inflammatory response in the sputum, bronchoalveolar lavage (BAL) and serum is known in the pathogenesis of PIBO disease. The use of macrolides has been suggested for the prophylactic treatment of patients with BO in order to benefit from the anti-inflammatory properties of such proinflammatory neutrophilic biomarkers as IL-1ß, IL-6 and IL-8 [8,9]. Accordingly, the patient was started on azithromycin for the maintenance treatment.

Clinical findings have identified a high level of inflammatory response in the presence of a SARS-CoV-2 infection, and this has been found to be associated with fatal uncontrolled pulmonary...
inflammation with genetic sensitivity. More than 40 candidate genes, including ACE2, interleukin 10 (IL-10), tumor necrosis factor (TNF) and vascular endothelial growth factor (VEGF), have been suggested to establish a ground for ARDS, while increased IL-6 and IL-8 levels have also been shown to be associated with adverse results of ARDS [10,11]. The similar pathogenesis of PIBO and SARS-CoV-2 infections facilitated the development of BO in the patient with the COVID-19 infection.

Molecular tools such as TNF-alpha blockers, montelukast, hemopoietic stem cell transplantation and microRNA have been considered as new treatment protocols for the treatment of BO, although more studies are required [1]. The selected treatment was not among the new generation treatment methods in the present study, since our patient was young.

**Conclusion**

The development of post-infectious bronchiolitis obliterans is frequently seen following viral bronchiolitis, especially in the winter months. Post-COVID-19 PIBO should be considered in children younger than 1 year of age and with long-standing respiratory symptoms, especially in families with a history of COVID-19 infection, although the presentation of viral infections has decreased since the announcement of the pandemic.

**References**